A humble opinion on the potential risk of clinical application of biological disease-modifying antirheumatic drugs
10.3760/cma.j.cn114015-20211227-01303
- VernacularTitle:生物类改善病情抗风湿药临床应用潜在风险刍议
- Author:
Junyu FAN
1
;
Ting JIANG
1
;
Dongyi HE
1
Author Information
1. 上海市光华中西医结合医院风湿免疫科，上海 200052
- Publication Type:Journal Article
- Keywords:
Rheumatic diseases;
Antirheumatic agents;
Biological products;
Drug-related side effects and adverse reactions
- From:
Adverse Drug Reactions Journal
2023;25(1):6-10
- CountryChina
- Language:Chinese
-
Abstract:
The biological disease-modifying antirheumatic drugs (DMARD) effectively prevented the progression of rheumatic diseases, improved the prognosis of patients, and promoted the innovation of the treatment pattern of rheumatic diseases. However, these drugs also have potential risks of inducing infection, malignant tumors, and immunogenicity of drugs, which should be paid attention to. At present, there are few relevant researches in China. This article introduces the research status of the above potential risks of biological DMARD in recent years, and puts forward some suggestions, hoping to contribute to the domestic related research and clinical safe drug use.
